In this secondary analysis of the Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by N-Terminal Pro–Brain Natriuretic Peptide Testing of Heart Failure Therapies (STRONG-HF) randomized clinical trial including 515 patients, 2 weeks after discharge, medium- to high-dose GDMT was prescribed in more than 90% of patients. The gene discussed is NPPB; the disease is heart failure.